TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00998634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LITHIUM CARBONATE
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LITHIUM CARBONATE
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
Study: NCT01600586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacifier-Activated-Lullaby system (PAL).
Description: Pacifier-Activated-Lullaby system (PAL).
Study: NCT03895320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Risk Assessment
Description: The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Score
Description: The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Messaging
Description: After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Water SSB Quiz
Description: The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Water SSB Score
Description: The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
Study: NCT01640496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
Study: NCT03895320

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Water SSB Messaging
Description: After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STI Screening
Description: All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI Screening
Description: All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
Study: NCT01227512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: 15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Restriction
Description: Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose
Study: NCT01640496

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
Study: NCT04373577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
Study: NCT00514254

Intervention type: OTHER
Intervention: questionnaire administration
Study: NCT04132557

Intervention type: DRUG
Intervention: Methylphenidate
Description: Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.

Intervention type: DRUG
Intervention: Lisdexamfetamine
Description: Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.

Intervention type: DRUG
Intervention: Atomoxetine
Description: Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.

Intervention type: DRUG
Intervention: Amphetamine
Description: Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Study: NCT00514254

Intervention type: OTHER
Intervention: questionnaire administration

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables

Intervention type: PROCEDURE
Intervention: evaluation of cancer risk factors
Study: NCT04132557

Intervention type: DRUG
Intervention: Dextroamphetamine
Description: Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Study: NCT00514254

Intervention type: PROCEDURE
Intervention: evaluation of cancer risk factors
Study: NCT00170079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition.
Study: NCT04395716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ResCure™
Description: Patients will be treated with nebulized ResCure™
Study: NCT04001153

Intervention type: OTHER
Intervention: Dental impressions
Description: Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state.
Study: NCT02036372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin bolus
Study: NCT04001153

Intervention type: OTHER
Intervention: Dental impressions
Description: Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state.

Intervention type: OTHER
Intervention: Dental impressions
Description: Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state.

Intervention type: OTHER
Intervention: Dental impressions
Description: Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state.
Study: NCT01394926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
Study: NCT04497987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.
Study: NCT02036372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIK infusion
Description: continuous infusion
Study: NCT00147381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours
Study: NCT05187026

Intervention type: OTHER
Intervention: electronic PROMs questionnaire
Description: Patients are asked to complete EPIC-26 questionnaire in paper and electronically
Study: NCT04017936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Active Treatment
Study: NCT02309099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
Study: NCT03529045

Intervention type: DEVICE
Intervention: Vagus Nerve Stimulation (VNS) Therapy
Description: The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
Study: NCT04092257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIA and thermocoagulation
Description: Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
Study: NCT03366142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: 0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
Study: NCT04497987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT04484805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE Condition
Description: Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Condition
Description: Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
Study: NCT04497987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etesevimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etesevimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etesevimab
Description: Administered IV.
Study: NCT04407728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early ultrasound screening
Description: Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2.
Study: NCT01069289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler)
Description: 2x160/4.5 microgram, inhalation, twice daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol (Oxis Turbuhaler)
Description: 2 X 4.5 microgram, inhalation, twice daily, 12 weeks
Study: NCT02826174

Intervention type: PROCEDURE
Group type: OTHER
Intervention: closed PKP under topical anesthesia
Description: a closed corneal transplantation under topical anesthesia with the anterior chamber maintained

Intervention type: PROCEDURE
Group type: OTHER
Intervention: closed PKP under topical anesthesia
Description: a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
Study: NCT04196283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: Intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous (IV) infusion
Study: NCT04209088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary ultrasounds
Description: Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator.
Study: NCT04197635

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximal functional capacity by cardiopulmonary exercise testing
Description: It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
Study: NCT02826174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed PKP under topical anesthesia
Description: a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
Study: NCT00000252

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Study: NCT04808479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imFREE mCBT
Description: The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth ED
Description: The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.